HIV infection and arterial inflammation assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET): A prospective cross-sectional study

Journal of Nuclear Cardiology

Volumn 22, Issue 2, 2015, Pages 372-380

  Knudsen, Andreas ^a,b   Hag, Anne Mette Fisker ^b   Loft, Annika ^b   von Benzon, Eric ^b   Keller, Sune H ^b   Møller, Holger Jon ^c   Lebech, Anne Mette ^a   Ripa, Rasmus Sejersten ^b   Kjær, Andreas ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Fluorodeoxyglucose (FDG); inflammation; PET CT imaging

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; IOVERSOL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL AORTA; ADULT; ARTERIAL WALL THICKNESS; ARTERITIS; ARTICLE; ASCENDING AORTA; CARDIOVASCULAR DISEASE; CAROTID ARTERY; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DESCENDING AORTA; DRUG UPTAKE; ENDOTHELIAL DYSFUNCTION; FEMALE; FRAMINGHAM RISK SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

ARTERITIS; FEMALE; FLUORODEOXYGLUCOSE F18; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84925505905     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-0032-0     Document Type: Article

References (32)

1. Freiberg MS, Chang C-CH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-22.
2. Kristoffersen US, Lebech A-M, Wiinberg N, Petersen CL, Hasbak P, Gutte H, et al. Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: A case-control myocardial perfusion scintigraphy study. PLoS ONE. 2013;8:e72066.
3. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2010;24:243-53.
4. Post WS, Budoff M, Kingsley L, Palella J, Frank J, Witt MD, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160(7):458-67.
5. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J. 2011;32:945-51.
6. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95.
7. Kristoffersen US, Wiinberg N, Petersen CL, Gerstoft J, Gutte H, Lebech A-M, et al. Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun. 2010;31:874-80.
8. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983-92.
9. Knudsen A, Mathiasen AB, Worck RH, Kastrup J, Gerstoft J, Katzenstein TL, et al. Angiographic features and cardiovascular risk factors in human immunodeficiency virus-infected patients with first-time acute coronary syndrome. Am J Cardiol. 2013;111:63-7.
10. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010;153:387-95.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
12. Crowe SM, Westhorpe CLV, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: The intersection between HIV infection and atherosclerosis. J Leukoc Biol. 2010;87:589-98.
13. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204:1227-36.
14. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA. 2012;308:379-86.
15. Pedersen SF, Hag AMF, Klausen TL, Ripa RS, Bodholdt RP, Kjær A. Positron emission tomography of the vulnerable atherosclerotic plaque in man—a contemporary review. Clin Physiol Funct Imaging. 2014;34:413-25.
16. Møller HJ, Hald K, Moestrup SK. Characterization of an enzyme-linked immunosorbent assay for soluble CD163. Scand J Clin Lab Invest. 2002;62:293-9.
17. Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: Underlying mechanisms and epidemiological aspects. AIDS Res Ther. 2013;10:32.
18. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-8.
19. 18F-FDG PET/CT imaging of vessel wall inflammation: The impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging. 2014;41:369-83.
20. Græbe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjær A. Molecular pathology in vulnerable carotid plaques: Correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714-21.
21. 18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm. 2012;9:26.
22. Græbe M, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. When to image carotid plaque inflammation with FDG PET/CT. Nucl Med Commun. 2010;31:773-9.
23. Martinez-Rodriguez I, Del Castillo-Matos R, Quirce R, Banzo I, Jimenez-Bonilla J, Martinez-Amador N, et al. Aortic 18F-FDG PET/CT uptake pattern at 60 min (early) and 180 min (delayed) acquisition in a control population: A visual and semiquantitative comparative analysis. Nucl Med Commun. 2013;34:926-30.
24. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20.
25. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr. 2007;44:493-9.
26. Noyes AM, Thompson PD. A systematic review of the time course of atherosclerotic plaque regression. Atherosclerosis. 2014;234:75-84.
27. Knudsen A, Katzenstein TL, Benfield T, Jorgensen NR, Kronborg G, Gerstoft J, et al. Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS. 2014;28:1171-9.
28. Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S. Reference intervals for common carotid intima-media thickness measured with echotracking: Relation with risk factors. Eur Heart J. 2013;34:2368-80.
29. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24.
30. 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun. 2010;31(5):423-9.
31. 18fluorine-labeled 2-deoxy-d-glucose positron emission tomography. J Am Coll Cardiol. 2011;58:603-14.
32. 18Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6.